Crowdonomics
Global Cancer Technology

Reg CF · Common Stock · Feb 2022

ClosedReg CFCommon Equity
via NetcapitalView campaign
Raised
$0 / $1.1M max
0% of ceiling
Investors
—
—
Post-money valuation
$26.7M
pre-money + amount raised

Raised over time

Cumulative raised
$2K$1K$0
Feb 8, 2022 · openedApr 29, 2022 · last reading
Deadline Apr 29, 2022 — 0 days out

Left axis: cumulative dollars raised. Live figures via Netcapital; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2019–FY2020 · hover for source
$0
−$674K
FY2019
$0
−$739K
FY2020
RevenueNet income
Metric
FY2019 audited
FY2020 audited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$674,005
-$739,118
Taxes paid
$0
$0
Balance sheet
Cash
$1,071
$49,137
Accounts receivable
$0
$0
Total assets
$251,420
$51,964
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$459,390
$500,281
Other
Headcount
1
1

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

1 amendment
  1. Apr 6, 2022
    Terms not yet extracted from this filing
    Form C/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.

Deal terms

Pre-money$26.7M
Post-money$26.7M
Price / share$2.00
Shares offered5,000

Offering details

Target$10,000
Max$1,070,000
Min investment$100
OpenedFeb 8, 2022
DeadlineApr 29, 2022
ClosedApr 29, 2022
Days active80

Links & provenance

Source: Manual
0001669191-22-000106

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.